HighVista Strategies LLC Sells 7,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

HighVista Strategies LLC decreased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 6.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 112,459 shares of the company’s stock after selling 7,330 shares during the period. HighVista Strategies LLC’s holdings in Enliven Therapeutics were worth $2,872,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Quest Partners LLC lifted its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Enliven Therapeutics by 12.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock worth $668,000 after purchasing an additional 2,944 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Enliven Therapeutics by 25.6% during the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock worth $441,000 after purchasing an additional 3,518 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,206 shares of the business’s stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $335,787.06. Following the transaction, the chief executive officer now owns 1,036,523 shares of the company’s stock, valued at approximately $28,514,747.73. This represents a 1.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 129,195 shares of company stock valued at $3,581,772 in the last three months. Corporate insiders own 29.20% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $24.43 on Tuesday. The business’s 50 day simple moving average is $26.80 and its 200 day simple moving average is $24.14. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $30.03.

Analysts Set New Price Targets

ELVN has been the topic of several recent research reports. Robert W. Baird increased their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.